Medistim — Earnings Release 2022

Apr 28, 2022

First quarter results for 2022 for Medistim ASA

First quarter results for 2022 for Medistim ASA

All time high sales for a quarter ending at MNOK 116.1 (MNOK 102.6), an increase of 13.2%. Sales growth driven by USA with currency neutral increase of 34.2%. Vascular business segment grows at 39.8%. Currency neutral sales of own products increased by 10.9% for the quarter. Operating result (EBIT) for the quarter ended at MNOK 33.4 (MNOK 29.1), a 15.0% increase. Medistim CEO receives Arthur D. Little Nordic Life Science Award for 2021. The General Meeting decided a dividend of NOK 3.75 per share, a total dividend payment of MNOK 68.4.